# Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration

> **NCT05296317** · NA · COMPLETED · sponsor: **Centre Georges Francois Leclerc** · enrollment: 97 (actual)

## Conditions studied

- Localized Breast Cancer

## Interventions

- **DRUG:** Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
- **DRUG:** Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)

## Key facts

- **NCT ID:** NCT05296317
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-02
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05296317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05296317, "Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05296317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*